

The content you trust, powering the features you need

EBSCO Discovery Service (EDS) brings together trusted medical content, librarian-guided design and practical AI enhancements to help clinicians and researchers move faster with confidence.

This guide can help you articulate the ongoing value of EDS to stakeholders across your organization.

Supporting your organization

As a medical knowledge professional, you support all areas of your organization. You ensure that end users have seamless, stable and secure access to the right content, all with the goal of delivering ROI on research investments.

EDS is critical to driving organizational value...



With leadership —

EDS offers unique content advantages with unparalleled indexing and integration of medical resources.



With clinicians —

EDS saves time at the point of need by delivering relevant, trusted results across multiple publishers in one search.



With IT and compliance teams —

EDS operates within a secure, stable framework with responsible AI practices and human oversight.

Discovery starts with what's underneath

Discovery platform features only deliver value when they're grounded in high-quality, well-curated content. EDS is built on a foundation of authoritative medical and health science resources, including:



Comprehensive coverage across nursing, allied health, biomedical and behavioral sciences



Unparalleled indexing from trusted sources including CINAHL, BIOSIS Previews, APA PsycInfo and MEDLINE



Thousands of journals, books, proceedings and more through EBSCO's included Biomedical Index



Enhanced Subject Precision that improves relevance, context and discoverability



Reduced silos yield better results

Where time and accuracy matter, fragmented searching slows progress and increases the risk of missed evidence. Unlike many competitors, EBSCO Discovery Service enables simultaneous searching across resources from EBSCO, APA, JAMA, ClinicalKey, Ovid and more, bringing licensed collections together in one unified experience. For clinicians and researchers, that means fewer platforms to navigate and faster path-to-answer.



A virtual medical library, built by librarians for clinical research

EBSCO Discovery Service is designed with librarians at the center, reflecting how medical libraries actually support clinicians, educators and researchers. Our librarian-approved discovery mirrors how users expect a medical library to work, with transparent indexing and metadata practices and search experiences aligned with evidence-based research and clinical inquiry.

Practical features that support real work

✔ **Natural Language Searching** allows clinicians to search keyword phrases and questions in familiar language without complex Boolean queries.

✔ **AI Insights** support faster comprehension and evaluation of relevant resources without replacing critical inquiry.

✔ **People Pages** surface author context and research to follow paths of critical inquiry.

✔ **Publication Alert Services** automate KOL monitoring to track emerging research in real time.

✔ **Author and Affiliation Searches** help identify and vet emerging thought leaders by querying author name, institution, or subject field to evaluate publication activity.

✔ **Citations and References Features** show citation counts and reference networks to pinpoint influential researchers and collaboration patterns.

✔ **Personal Folders, Search Alerts, and Share Tools** allow researchers to set alerts, save literature sets and share permalinks with collaborators.

AI Insights

Peer reviewed | Academic Journal

Phase I pharmacokinetic study of single agent trametinib in patients with advanced cancer and hepatic dysfunction.

By: Voon, Pei Jye; Chen, Eric X.; Chen, Helen X.; +16 more • In: Journal of Experimental & Clinical Cancer Research (17569966), 07/02/2022, volume 41, issue 1, pages 1-15 (15p) • Academic Search Ultimate

Background: Trametinib is an oral MEK 1/2 inhibitor, with a single agent recommended phase 2 dose (RP2D) of 2 mg daily (QD). This study was designed to evaluate RP2D, maximum tolerated dose (MTD), and pharmacokinetic (PK) profi... [Show more](#)

Subjects: [Cancer patients](#); [Pharmacokinetics](#); [Serum albumin](#)

Access options

8 citations in Scopus®

Generate AI Insights beta

Insights

- The study determined the recommended phase 2 dose (RP2D) of trametinib in patients with mild hepatic dysfunction to be 2 mg, while insufficient data was available to declare an RP2D for moderate and severe hepatic dysfunction.
- No dose-limiting toxicities (DLT) were observed in the highest dose cohorts that reached three evaluable patients - 1.5 mg QD in the moderate group, and 1 mg QD in the severe group.
- Pharmacokinetic (PK) parameters of trametinib were numerically lower in moderate and severe hepatic dysfunction groups compared to normal and mild groups, though the differences were not statistically significant.
- The study faced challenges in patient recruitment, particularly in the severe hepatic dysfunction group, limiting the conclusions that can be drawn about the safety of trametinib in this population.
- The study provides guidance for future clinical trials evaluating trametinib in combination with other agents in patients with varying degrees of hepatic dysfunction.

Disclaimer: These insights are generated by AI based on the content of the source document. Information quality may vary and AI Insights should be validated for accuracy. Insights are newly generated with each request and are not reproducible.

Did you find these insights helpful?

Yes

No

By leveraging these capabilities, researchers and clinicians can generate relevant insights, prepare evidence packs, and boost strategic, data-driven collaboration.

Search Alerts

Alert name

medical devices AND artificial intelligence AND prognostics

59/255

Description (optional)

Ongoing published research and insights on this topic.

54/300

Frequency

Daily



Backed by security, stability, and accessibility


In clinical environments, reliability and compliance are non-negotiable. EBSCO enforces robust security practices behind all AI-powered features and follows responsible AI tenants with human-in-the-loop development. Our platform and features are designed for stability, continuity and long-term support — not a short-term splash.

Furthermore, EBSCO adheres to strong accessibility standards in all areas of development to ensure equitable access for all users. **Our conformance reports and statements** are regularly updated and publicly available to view on EBSCO Connect.

What your investment delivers

Your EBSCO Discovery Service investment supports:

- ✓ Faster, more confident clinical and research decisions
- ✓ Stronger visibility and use of licensed medical collections
- ✓ Streamlined workflows across publishers and platforms
- ✓ Responsible AI enhancements grounded in trusted indexing
- ✓ A secure, stable and accessible discovery environment



Let's talk about your discovery strategy

If you're navigating internal questions about discovery platforms or exploring ways to optimize EBSCO Discovery Service for your medical team, we're here to support you.

Start a conversation with your EBSCO representative today.